Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans
Publication date
2020-01-14
Authors
Goya, María Eugenia
Xue, Feng
Sampedro-Torres-Quevedo, Cristina
Arnaouteli, Sofia
Riquelme-Dominguez, Lourdes
Romanowski, Andres
Brydon, Jack
Ball, Kathryn L.
Stanley-Wall, Nicola R.
Doitsidou, Maria
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
How the gut microbiome affects Parkinson's disease remains unclear. Goya et al. show that the probiotic B. subtilis strain PXN21 inhibits and clears α-synuclein aggregation in a C. elegans model. The bacterium acts via metabolites and biofilm formation to activate protective pathways in the host, including DAF-16/FOXO and sphingolipid metabolism.
Keywords
B. subtilis, biofilm, C. elegans, DAF-16/FOXO, dietary restriction, microbiota, Parkinson's disease, probiotics, sphingolipid metabolism, α-synuclein, General Biochemistry,Genetics and Molecular Biology
Citation
Goya, M E, Xue, F, Sampedro-Torres-Quevedo, C, Arnaouteli, S, Riquelme-Dominguez, L, Romanowski, A, Brydon, J, Ball, K L, Stanley-Wall, N R & Doitsidou, M 2020, 'Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans', Cell Reports, vol. 30, no. 2, pp. 367-380.e7. https://doi.org/10.1016/j.celrep.2019.12.078